Results 91 to 100 of about 10,848 (199)

PDB: 3PP4, Cd20 in complex with obinutuzumab (310K, 37°C, 100 ns)

, 2023
Molecular Dynamics Simulations (100 nanoseconds) of Cd20 in complex with obinutuzumab (310K, 37 ...
Stan, Razvan
core   +1 more source

Decision‐Making on First‐Line Treatment Alternatives in Chronic Lymphocytic Leukemia: A Multi‐Criteria Decision Analysis to Elicit Stakeholders' Preferences in Italy

Hematological Oncology, Volume 44, Issue 6, November 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries. The introduction of targeted therapies has expanded first‐line treatment options, which differ across multiple relevant dimensions, making therapeutic decisions increasingly challenging.
Paolo Sportoletti, Felice Bombaci, Chiara Cernetti, Alessandra Di Costanzo, Francesca Fiorentino, Sara Manurita, Andrea Marcellusi, Riccardo Mercati, Massimo Riccaboni, Chiara Vassallo, Antonio Cuneo   +10 more
wiley   +1 more source

Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes’ army

Future Science OA, 2019
Aim: To analyze the effects of subcutaneous or intravenous rituximab + lymphokine-activated killer cells, obinutuzumab or ibrutinib on natural killer (NK) cell levels in chronic lymphocytic leukemia and follicular lymphoma patients.
Ricardo García-Muñoz, María-Josefa Nájera, Jesús Feliu, Judith Antón-Remírez, Enrique Ramalle-Gómara, Raquel Marín-Gorricho, Raisa Peralta, Elena Gutiérrez-Gamarra, Jessica Nuñez-Rodriguez, Ricardo Zafra-Morales, Lorea Aguinaga, María-Jose Nebot-Villacampa, Prisma-Monserrat Hernandez-Pérez, Giovanna Farfán-Quiroga, Carlos Panizo, Elena Domínguez-Garrido   +15 more
doaj   +1 more source

Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL – real-life data analysis of the Polish Adult leukemia group

Leukemia and Lymphoma
This is a retrospective analysis of 220 patients with chronic lymphocytic leukemia (CLL) and comorbid conditions defined as a presence of cumulative illness rating scale (CIRS) >6 and/or creatinine clearance 6 impacted the probability of response or ...
K. Zielonka, Błażej Izdebski, Joanna Drozd-Sokołowska, Katarzyna Pruszczyk-Matusiak, Bartosz Puła, Kamil Wiśniewski, W. Sawicki, E. Kalicińska, Paula Jabłonowska-Babij, Aleksandra Butrym, T. Buczek, E. Subocz, J. Hałka, M. Witkowska, Mateusz Wilk, Maria Hryniewiecka, Karolina Gruenpeter, E. Cichocka, Piotr Halicki, K. Wdowiak, E. Iskierka-Jażdżewska, A. Kopińska, A. Szlauer-Stefańska, Agnieszka Szymczyk, A. Wolska-Washer, Jolanta Kowalczyk, Tomasz Wróbel, Iwona Hus, Krzysztof Jamroziak   +28 more
semanticscholar   +1 more source

PDB: 3PP4, Cd20 in complex with obinutuzumab (311K, 38°C, 100 ns)

, 2023
Molecular Dynamics Simulations (100 nanoseconds) of Cd20 in complex with obinutuzumab (311K, 38 ...
Stan, Razvan
core   +1 more source

The anti‐CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B‐cell lymphomas

British Journal of Haematology
Follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) are characterized by a continuous incidence of relapse and increasing resistance to therapy.
R. Lakhotia, C. Melani, Stafania Pittaluga, Max J. Gordon, James D. Phelan, J. Muppidi, Atekelt Y. Tadese, Sarah Evans, E. Jaffe, L. Staudt, Wyndham H. Wilson, M. Roschewski   +11 more
semanticscholar   +1 more source

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy

, 2017
Othman Al-Sawaf, Kirsten Fischer, Anja Engelke, Natali Pflug, Michael Hallek, Valentin Goede German CLL Study Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany Abstract: For decades, treatment of chronic ...
Hallek M, Engelke A, Al-Sawaf O, Goede V, Fischer K, Pflug N   +5 more
core  

Obinutuzumab Effective in Follicular Lymphoma, but at a Cost

, 2017
In a phase III trial involving more than 1,200 patients with follicular lymphoma, obinutuzumab plus chemotherapy reduced the risk of disease progression, relapse, or death by 34% compared with rituximab plus chemotherapy.

core   +1 more source

Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)

OncoImmunology, 2018
Treatment with monoclonal antibodies has revolutionized clinical medicine, especially in the fields of cancer and immunology. One of the oldest antibodies, which is widely used for the treatment of lymphomas and autoimmune diseases, is the anti-CD20 ...
Shlomo Elias, Shira Kahlon, Rebecca Kotzur, Noah Kaynan, Ofer Mandelboim   +4 more
doaj   +1 more source

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

, 2019
Background Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard first-line treatments in chronic lymphocytic leukaemia.
Gribben, John G., Novak, Jan, Ben-Yehuda, Dina, Zhou, Cathy, Samoilova, Olga, DEMİRKAN, FATİH, Flinn, Ian W., Hsu, Emily, Anz, Bertrand, Larratt, Loree, Moreno, Carol, Lih, Chih-Jian, Simkovic, Martin, Greil, Richard, Strugov, Vladimir, James, Danelle F., Tedeschi, Alessandra, Gill, Devinder, Clow, Fong, Styles, Lori   +19 more
core   +1 more source